Cargando…
PB1773: AML AND MDS WITH RARA OVEREXPRESSION: MOLECULAR AND CLINICAL FEATURES OF PATIENTS ENROLLED IN A PHASE 2 TRIAL EVALUATING TAMIBAROTENE-BASED THERAPY
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429971/ http://dx.doi.org/10.1097/01.HS9.0000973948.50253.dc |
| _version_ | 1785090844630450176 |
|---|---|
| author | de Botton, Stéphane Cluzeau, Thomas Vigil, Carlos Cook, Rachel Rousselot, Philippe Rizzieri, David Liesveld, Jane Fenaux, Pierre Braun, Thorsten Pigneux, Arnaud Peterlin, Pierre Paul, Sofia Rajagopal, Nisha Carulli, John Roth, David Volkert, Angela Malak, Tanya Abdul Kelly, Michael Klimek, Virginia Stein, Eytan |
| author_facet | de Botton, Stéphane Cluzeau, Thomas Vigil, Carlos Cook, Rachel Rousselot, Philippe Rizzieri, David Liesveld, Jane Fenaux, Pierre Braun, Thorsten Pigneux, Arnaud Peterlin, Pierre Paul, Sofia Rajagopal, Nisha Carulli, John Roth, David Volkert, Angela Malak, Tanya Abdul Kelly, Michael Klimek, Virginia Stein, Eytan |
| author_sort | de Botton, Stéphane |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10429971 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104299712023-08-17 PB1773: AML AND MDS WITH RARA OVEREXPRESSION: MOLECULAR AND CLINICAL FEATURES OF PATIENTS ENROLLED IN A PHASE 2 TRIAL EVALUATING TAMIBAROTENE-BASED THERAPY de Botton, Stéphane Cluzeau, Thomas Vigil, Carlos Cook, Rachel Rousselot, Philippe Rizzieri, David Liesveld, Jane Fenaux, Pierre Braun, Thorsten Pigneux, Arnaud Peterlin, Pierre Paul, Sofia Rajagopal, Nisha Carulli, John Roth, David Volkert, Angela Malak, Tanya Abdul Kelly, Michael Klimek, Virginia Stein, Eytan Hemasphere Publication Only Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429971/ http://dx.doi.org/10.1097/01.HS9.0000973948.50253.dc Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only de Botton, Stéphane Cluzeau, Thomas Vigil, Carlos Cook, Rachel Rousselot, Philippe Rizzieri, David Liesveld, Jane Fenaux, Pierre Braun, Thorsten Pigneux, Arnaud Peterlin, Pierre Paul, Sofia Rajagopal, Nisha Carulli, John Roth, David Volkert, Angela Malak, Tanya Abdul Kelly, Michael Klimek, Virginia Stein, Eytan PB1773: AML AND MDS WITH RARA OVEREXPRESSION: MOLECULAR AND CLINICAL FEATURES OF PATIENTS ENROLLED IN A PHASE 2 TRIAL EVALUATING TAMIBAROTENE-BASED THERAPY |
| title | PB1773: AML AND MDS WITH RARA OVEREXPRESSION: MOLECULAR AND CLINICAL FEATURES OF PATIENTS ENROLLED IN A PHASE 2 TRIAL EVALUATING TAMIBAROTENE-BASED THERAPY |
| title_full | PB1773: AML AND MDS WITH RARA OVEREXPRESSION: MOLECULAR AND CLINICAL FEATURES OF PATIENTS ENROLLED IN A PHASE 2 TRIAL EVALUATING TAMIBAROTENE-BASED THERAPY |
| title_fullStr | PB1773: AML AND MDS WITH RARA OVEREXPRESSION: MOLECULAR AND CLINICAL FEATURES OF PATIENTS ENROLLED IN A PHASE 2 TRIAL EVALUATING TAMIBAROTENE-BASED THERAPY |
| title_full_unstemmed | PB1773: AML AND MDS WITH RARA OVEREXPRESSION: MOLECULAR AND CLINICAL FEATURES OF PATIENTS ENROLLED IN A PHASE 2 TRIAL EVALUATING TAMIBAROTENE-BASED THERAPY |
| title_short | PB1773: AML AND MDS WITH RARA OVEREXPRESSION: MOLECULAR AND CLINICAL FEATURES OF PATIENTS ENROLLED IN A PHASE 2 TRIAL EVALUATING TAMIBAROTENE-BASED THERAPY |
| title_sort | pb1773: aml and mds with rara overexpression: molecular and clinical features of patients enrolled in a phase 2 trial evaluating tamibarotene-based therapy |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429971/ http://dx.doi.org/10.1097/01.HS9.0000973948.50253.dc |
| work_keys_str_mv | AT debottonstephane pb1773amlandmdswithraraoverexpressionmolecularandclinicalfeaturesofpatientsenrolledinaphase2trialevaluatingtamibarotenebasedtherapy AT cluzeauthomas pb1773amlandmdswithraraoverexpressionmolecularandclinicalfeaturesofpatientsenrolledinaphase2trialevaluatingtamibarotenebasedtherapy AT vigilcarlos pb1773amlandmdswithraraoverexpressionmolecularandclinicalfeaturesofpatientsenrolledinaphase2trialevaluatingtamibarotenebasedtherapy AT cookrachel pb1773amlandmdswithraraoverexpressionmolecularandclinicalfeaturesofpatientsenrolledinaphase2trialevaluatingtamibarotenebasedtherapy AT rousselotphilippe pb1773amlandmdswithraraoverexpressionmolecularandclinicalfeaturesofpatientsenrolledinaphase2trialevaluatingtamibarotenebasedtherapy AT rizzieridavid pb1773amlandmdswithraraoverexpressionmolecularandclinicalfeaturesofpatientsenrolledinaphase2trialevaluatingtamibarotenebasedtherapy AT liesveldjane pb1773amlandmdswithraraoverexpressionmolecularandclinicalfeaturesofpatientsenrolledinaphase2trialevaluatingtamibarotenebasedtherapy AT fenauxpierre pb1773amlandmdswithraraoverexpressionmolecularandclinicalfeaturesofpatientsenrolledinaphase2trialevaluatingtamibarotenebasedtherapy AT braunthorsten pb1773amlandmdswithraraoverexpressionmolecularandclinicalfeaturesofpatientsenrolledinaphase2trialevaluatingtamibarotenebasedtherapy AT pigneuxarnaud pb1773amlandmdswithraraoverexpressionmolecularandclinicalfeaturesofpatientsenrolledinaphase2trialevaluatingtamibarotenebasedtherapy AT peterlinpierre pb1773amlandmdswithraraoverexpressionmolecularandclinicalfeaturesofpatientsenrolledinaphase2trialevaluatingtamibarotenebasedtherapy AT paulsofia pb1773amlandmdswithraraoverexpressionmolecularandclinicalfeaturesofpatientsenrolledinaphase2trialevaluatingtamibarotenebasedtherapy AT rajagopalnisha pb1773amlandmdswithraraoverexpressionmolecularandclinicalfeaturesofpatientsenrolledinaphase2trialevaluatingtamibarotenebasedtherapy AT carullijohn pb1773amlandmdswithraraoverexpressionmolecularandclinicalfeaturesofpatientsenrolledinaphase2trialevaluatingtamibarotenebasedtherapy AT rothdavid pb1773amlandmdswithraraoverexpressionmolecularandclinicalfeaturesofpatientsenrolledinaphase2trialevaluatingtamibarotenebasedtherapy AT volkertangela pb1773amlandmdswithraraoverexpressionmolecularandclinicalfeaturesofpatientsenrolledinaphase2trialevaluatingtamibarotenebasedtherapy AT malaktanyaabdul pb1773amlandmdswithraraoverexpressionmolecularandclinicalfeaturesofpatientsenrolledinaphase2trialevaluatingtamibarotenebasedtherapy AT kellymichael pb1773amlandmdswithraraoverexpressionmolecularandclinicalfeaturesofpatientsenrolledinaphase2trialevaluatingtamibarotenebasedtherapy AT klimekvirginia pb1773amlandmdswithraraoverexpressionmolecularandclinicalfeaturesofpatientsenrolledinaphase2trialevaluatingtamibarotenebasedtherapy AT steineytan pb1773amlandmdswithraraoverexpressionmolecularandclinicalfeaturesofpatientsenrolledinaphase2trialevaluatingtamibarotenebasedtherapy |